Based on the requirement of PAR2 for TGF-β1-dependent migration and invasion, we have postulated earlier that combined treatment for cancer patients with inhibitors of TGF-β/ALK5 and PAR2 signaling may be more effective than a single treatment regimen. Here, TGFB1 is linked to cancer.